Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. Founded by internationally recognized leaders in stem cell transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/16/16 | $48,500,000 | Series A |
Atlas Venture Third Rock Ventures | undisclosed |
| 05/02/17 | $50,000,000 | Series B |
Access Industries Atlas Venture Be The Match BioTherapies Casdin Capital Partners Innovation Fund Third Rock Ventures | undisclosed |
| 04/09/18 | $52,000,000 | Series C |
Access Industries Be The Match BioTherapies Casdin Capital  EcoR1 Capital Eventide Asset Management Watermill Asset Management | undisclosed |
